Savara Inc (SVRA) stock intrinsic value fair value estimate & owner earnings analysis

Savara is a clinical-stage biopharmaceutical company whose entire near-term value rests on one drug: molgramostim inhalation solution, branded MOLBREEVI, for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) -- an ultra-rare lung disease in which a signaling protein (GM-CSF) fails to clear a fatty substance from the lungs' air sacs. Today the only treatment is whole lung lavage, an invasive procedure performed under general anesthesia that must be repeated over a patient's lifetime. Savara has never generated meaningful commercial revenue; essentially every dollar spent has gone into developing, and now seeking approval for, MOLBREEVI. The company's Phase 2/3 trial results were published in the New England Journal of Medicine in 2020 and showed a positive treatment effect. Savara submitted its U.S. approval application (BLA) in March 2025; the FDA declined to accept that first submission in May 2025, Savara resubmitted in December 2025, and the FDA formally accepted it with Priority Review in February 2026. In April 2026 the FDA classified follow-up data as a "major amendment," triggering a routine three-month extension -- the agency has said this was not due to a safety, efficacy or manufacturing concern. The new target decision date is November 22, 2026, about two months from today. European and U.K. decisions are expected in late 2026 / the first half of 2027, with applications already accepted for review. Savara has already built a roughly 30-person commercial team ahead of a hoped-for launch, and is burning cash at close to $150 million a year against roughly $173 million of cash and investments as of mid-2026. This makes Savara a binary, near-term valuation, so we built three distinct stories rather than a single blended number. Bear case ($0.00/share): The FDA declines to approve MOLBREEVI. This would be Savara's second regulatory setback on this drug, and the company has no other clinical asset to fall back on. A rejection removes the only identifiable source of future value; the cash on hand would fund a limited runway, a debt facility the company has arranged becomes available only upon approval, and the practical outcome is a distressed raise, a sale, or a wind-down. We don't see a named, evidenced source of continuing value in that scenario, so the shares are worth at or near zero -- not because a specific liability swamps the assets, but because nothing else is behind the one program. Base case (approx $5.25/share): MOLBREEVI is approved on or close to schedule and launches in the U.S. in early 2027 using the commercial team already hired. We size the U.S. opportunity using Savara's own 2025 insurance-claims analysis, which identified about 5,500 diagnosed autoimmune PAP patients, and price the drug in line with the company's own guidance of roughly $400,000-$500,000 per patient per year before discounts -- consistent with how other ultra-rare inhaled biologics have been priced. Moving patients off an invasive, recurring hospital procedure takes time (diagnosis, physician education, insurance prior authorization for an expensive drug), so we assume a gradual ramp reaching about a fifth of identified U.S. patients by year six or seven, with a smaller, later contribution from the U.K./EU4 markets (Germany, France, Italy, Spain, U.K.) where filings are underway but government pricing is typically lower. On that path, revenue grows toward roughly $500-550 million a year by the early 2030s and the business becomes solidly cash-generative around 2028-2029 as the already-built commercial infrastructure gains scale. Because the drug's Orphan Drug exclusivity runs seven years from approval (to roughly 2033), and because drug-device combination products like this one (paired with a specific handheld nebulizer) have historically been hard for competitors to copy exactly, we assume most of the earnings power persists, at a discount, beyond that date rather than collapsing -- but we assume no new growth driver beyond the current disease. Bull case (approx $16.50/share): Approval comes without further delay, the European and U.K. decisions land on their stated timelines, and Savara's own commercial and medical-education effort executes faster -- reaching roughly a third of identified U.S. patients and a fifth of European patients, on the same disease population and the same pricing as the base case, not a bigger market or a higher price. Savara cannot be valued the way an established, cash-generating business can. Its near-term worth depends on an FDA decision about two months away that could go either way, and its financial history to date is really the cost of getting to that decision: owner earnings worsened from roughly negative $43 million in 2021 to roughly negative $119 million in 2025, reflecting regulatory and pre-launch commercial spending rather than a weakening existing business. The margin-of-safety price sits well below even the base case because a rejection is a real, live possibility with no fallback business behind it. What would prove this wrong: an approval that comes with unexpectedly weak insurance-reimbursement terms, or slower-than-assumed patient adoption, would push real results toward the bear case even with the drug approved -- payer pushback on a drug priced near half a million dollars a year is common. Conversely, if Savara's ongoing claims analyses keep finding more diagnosed patients than assumed here (its 2025 analysis already found over 50% more patients than an earlier estimate), the base and bull cases understate the opportunity. We could not find any signed payer contract or locked-in launch price in the company's disclosures -- the $400,000-$500,000 figure is management's stated pricing intent, not a committed number, and we treated it as directional rather than as fact.